The Kansas Bioscience Authority, of Topeka, appointed its inaugural nine members: Victoria Franchetti Haynes, Sandra Lawrence, Bill Sanford, Clay Blair, David Franz, Dolph Simons, Dan Glickman, Jim Barone and Stephen O'Connor.
Oxxon Therapeutics Inc., of Oxford, UK, appointed Benjamin McNeil Bailey vice president of finance and operations.
Power3 Medical Products Inc., of The Woodlands, Texas, appointed Zouhair Atassi and Thomas Watts to its scientific advisory board.
Pozen Inc., of Chapel Hill, N.C., named William Hodges chief financial officer and senior vice president of finance and administration.
Serologicals Corp., of Atlanta, appointed Robert Brown vice president, corporate development.
Tercica Inc., of South San Francisco, appointed Stephen Rosenfield senior vice president of legal affairs, general counsel and secretary.
TheraQuest Biosciences, of Blue Bell, Pa., appointed to its scientific advisory board Richard Payne, Troels Jensen, Arthur Weaver, Raymond Sinatra, Arthur Lipman and Frank Porreca.
VaxGen Inc., of Brisbane, Calif., appointed Randall Caudill chairman, and gave CEO Lance Gordon the additional title of president.
VirtualScopics LLC, of Rochester, N.Y., appointed Stuart Shapiro CEO.
Xanodyne Pharmaceuticals Inc., of Florence, Ky., appointed Daniel Docherty vice president of sales.
Xcyte Therapies Inc., of Seattle, appointed Lawrence Romel vice president of clinical operations and project management.